SCM
Sarissa Capital Management Portfolio holdings
AUM
$154M
This Quarter Return
+25.25%
1 Year Return
-6.05%
3 Year Return
-7.91%
5 Year Return
+32.47%
10 Year Return
+262.41%
AUM
$980M
AUM Growth
+$980M
(+15%)
Cap. Flow
+$5.52M
Cap. Flow
% of AUM
0.56%
Top 10 Holdings %
Top 10 Hldgs %
99.98%
Holding
12
New
1
Increased
3
Reduced
1
Closed
–
Top Buys
| 1 |
BioCryst Pharmaceuticals
BCRX
|
$24.7M |
| 2 |
SRSAW
Sarissa Capital Acquisition Corp. Warrants
SRSAW
|
$5M |
| 3 |
Alkermes
ALKS
|
$2.49M |
| 4 |
Mersana Therapeutics
MRSN
|
$2.39M |
Top Sells
| 1 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
$29.1M |
Sector Composition
| 1 | Healthcare | 99.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ironwood Pharmaceuticals
IRWD
$214M
| $160M | 16.32% | 14,040,000 | – | – |
|
|
2
Alkermes
ALKS
$4.78B
| $159M | 16.19% | 7,950,000 +125,000 | +2% | +$2.49M |
|
3
Biogen
BIIB
$19.4B
| $157M | 16.07% | 643,000 | – | – |
|
4
Jazz Pharmaceuticals
JAZZ
$7.75B
| $153M | 15.63% | 928,100 | – | – |
|
|
ALXN
5
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $125M | 12.72% | 797,740 | – | – |
|
6
Innoviva
INVA
$1.29B
| $79.5M | 8.11% | 6,414,000 | – | – |
|
|
7
Mersana Therapeutics
MRSN
$36.5M
| $77.9M | 7.95% | 2,927,000 +90,000 | +3% | +$2.39M |
|
|
8
BioCryst Pharmaceuticals
BCRX
$1.74B
| $60.9M | 6.22% | 8,175,000 +3,314,000 | +68% | +$24.7M |
|
|
SRSAW
9
DELISTED
Sarissa Capital Acquisition Corp. Warrants
SRSAW
| $5M | 0.51% | +3,333,333 | New | +$5M |
|
|
RGLS
10
DELISTED
Regulus Therapeutics
RGLS
| $2.5M | 0.26% | 1,851,851 | – | – |
|
|
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $219K | 0.02% | 1,000 | – | – |
|
|
ICPT
12
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $23K | ﹤0.01% | 950 -1,200,050 | -100% | -$29.1M |
|